A Dutch ruling is raising complex questions about how the Netherlands will regulate sensitive biomedical research.
No takes yet. Share an insight, caveat, or question.
Martin Enserink (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: